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Abstract
Cancer is the second cause of mortality worldwide. Angiogenesis is an important process 
involved in the growth of primary tumors and metastasis. New approaches for controlling 
the cancer progression and invasiveness can be addressed by limiting the angiogenesis 
process. An increasingly large number of natural compounds are evaluated as angiogen-
esis inhibitors. The chorioallantoic membrane (CAM) assay represents an in vivo attrac-
tive experimental model for cancer and angiogenesis studies as prescreening to the murine 
models. Since the discovery of tumor angiogenesis, the CAM has been intensively used in 
cancer research. The advantages of this in vivo technique are in terms of low time-consum-
ing, costs, and a lower number of sacrificed animals. Currently, a great number of natural 
compounds are being investigated for their effectiveness in controlling tumor angiogen-
esis. Potential reducing of angiogenesis has been investigated by our group for pentacyclic 
triterpenes, in various formulations, and differences in their mechanism were registered. 
This chapter aims to give an overview on a number of phytocompounds investigated using 
in vitro, murine models and the chorioallantoic membrane assay as well as to emphasize the 
use of CAM assay in the study of natural compounds with potential effects in malignancies.
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1. Introduction
Angiogenesis represents the process by which new vessels are formed from preexisting vessels 
[1] and has important implications associated with tumor growth and metastasis [2]. Studies 
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have shown that neovascularization is essential for tumor survival and growth, whereas in 
angiogenic absent conditions, tumor may display necrosis or even apoptosis [3, 4]. The angio-
genic switch represents the process in which endothelial cells are led to a rapid growth state 
induced by stimuli secreted by the tumor microenvironment, comprising tumor and stromal 
cells, extracellular matrix components, immunologic cells, fibroblasts, adipocytes, muscle cells, 
and pericytes [5]. The switch may also involve downregulation of endogenous inhibitors of 
angiogenesis such as endostatin, angiostatin, or thrombospondin.
The undergoing of tumor angiogenesis represents a four-step process [6]: (i) tissue base-
ment membrane injury; (ii) migration of endothelial cells, activated by angiogenic factors; 
(iii) endothelial cell proliferation and stabilization; (iv) continuous angiogenesis induced by 
angiogenic factors. Therefore, key elements in the angiogenesis process are the endogenous 
angiogenic factors. The most relevant angiogenic activators, signal mediators, and signaling 
effects are represented in Figure 1.
A class of proteins that is widely responsible for tumor angiogenesis is represented by growth 
factors, such as the vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), 
platelet-derived endothelial growth factor (PDGF), tumor necrosis factor-α (TNF-α), epider-
mal growth factor (EGF), placental growth factor (PGF), transforming growth factor (TGF), 
granulocyte colony stimulating factor (GCSF), hepatocyte growth factor (HGF), angiostatin, 
and angiogenin [7]. However, VEGF is thought to be the main proangiogenic growth fac-
tor, because it induces all four phases of angiogenesis by augmenting vascular permeability, 
endothelial cell proliferation, endothelial cell migration, and capillary like tube formation [8]. 
Angiogenic cytokines or other growth factors such as VEGF are expressed under hypoxia 
conditions or by various oncogenes (e.g., mutant ras, erbB-2/HER2) [9].
As shown in Figure 1, after binding the tyrosine kinase specific domain of the receptors, mul-
tiple ways of signaling are possible for the angiogenic factors. Important molecular mecha-
nisms involve activation of RAS/RAF1/kinase through the extracellular signal (ERK-1 și-2), 
inducing proliferation and differentiation; RAS/p38 mitogen-activated kinase (MAPK) and 
JUN/kinase 1-3 N-terminal, modulating inflammation, apoptosis, and differentiation; phos-
fatidyl-3-inositol kinase-1 (PI3K) and AKT dependent, regulating cell survival, mammalian 
receptor for rapamycin (mTOR), highly involved in proliferation and cell growth. Other 
inductor factors of the signaling pathways of angiogenesis are found in the cytoplasm (e.g., 
GAB1, SHC, SRC, PI3K, and phosfolipase γ C) [10].
VEGF and its receptors, the VEGFR family, remain intensively researched for targeting angio-
genesis in different tumors. At the same time, other angiogenesis suppressing-related targets 
are being studied for the development of anticancer therapies for tumors resistant to anti-
VEGF therapy. A number of therapeutic agents are currently in use for several malignan-
cies: monoclonal antibodies against angiogenic growth factors (e.g., antibody against VEGF, 
Bevacizumab), inhibitors of angiogenic factors synthesis (e.g., mTOR inhibitor Rapamycin), 
and inhibitors of angiogenic factor receptors (tyrosine-kinase inhibitors, e.g., imatinib and 
sorafenib) [11]. Unfortunately, clinical response to the new molecular advances in cancer 
therapy by targeting angiogenesis is unsatisfactory. Resistance and low survival rates are sig-
naled. New therapeutic approaches with minimal side effects are desired to act by targeting 
the multiple factors that are activated during tumor progression.
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Based on the preventive effect that healthy diets have on the epidemiology of cancer, medici-
nal plants, spices, fruits, and vegetables represent an interesting source of phytochemicals. 
Natural compounds or even plant extracts are now considered important and accessible 
therapeutic or chemopreventive agents in cancer. In the search of the suitable phytocom-
pounds to test for specific effects, virtual screening methods can be successfully applied 
in the selection of selective compounds for specific targets [12]. To avoid lack of selectiv-
ity, computational filtering schemes can be used [13]. Extensive studies demonstrate the 
high potential of plant-derived chemicals in controlling tumor angiogenesis with minimal 
secondary effects and drug resistance, by targeting multiple key pathways in a synergistic 
manner.
2. Experimental models for tumor angiogenesis: focus on the CAM assay
An important issue in angiogenesis studies is the appropriate choice of the assays. To evaluate 
the efficacy of potential phytocompounds and to identify potential targets within the angio-
genic process, several methods both in vitro and in vivo can be applied. Each of them having 
one or more drawbacks, ideally more techniques are to be applied. In vitro techniques are 
used by co-culturing endothelial cell and other tumor microenvironment factors with tumor 
Figure 1. Angiogenic factors and signaling pathways involved in angiogenesis mediation. Abbreviations: Akt, RAC-
alpha serine/threonine-protein kinase, ERK1/2, mitogen-activated protein kinase 1/2, FAK, focal adhesion kinase; FGFR, 
fibroblast growth factor receptor; IGFR, insulin growth factor receptor; MAPK, mitogen-activated protein kinases; NOS, 
nitric oxide synthase; p38, mitogen-activated protein kinase 11; PDGFR, olated-delivered endothelial growth factor 
receptor; PI3K, phosphatidylinositol 4,5-bisphosphate 3-kinase; PLCγ, phospholipase C gamma; Smad, Smad protein; 
Src, proto-oncogene tyrosine-protein kinase; TGFα-R, transforming growth factor α receptor; Tie, angiopoietin receptor; 
VEGFR, vascular endothelial growth factor receptor.
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cells in 2D or even 3D models which facilitate the identification of the involved molecular 
mechanisms. Despite the advances made in the direction of designing in vitro assays, the in 
vivo environment can be difficultly reproduced with such protocols [14]. To better assess the 
key aspects of tumor angiogenesis and therapeutic approaches, in vivo assays can be applied, 
such as the chick chorioallantoic membrane (CAM), the zebrafish, the sponge implantation, 
the corneal, or dorsal air sac and tumor angiogenesis models in rodents or rabbits [15]. Several 
drawbacks can still be cited, especially for the murine models, including high costs, complex 
technical and surgical abilities, and important quantities of test compounds.
2.1. Chorioallantoic membrane assay
The chorioallantoic membrane (CAM) assay represents an attractive in vivo experimental 
model for angiogenesis and cancer studies. The advantages of this in vivo technique in terms 
of costs, time, simplicity, reproducibility, and ease of the approval by the ethic committee 
make it a good prescreening assay to murine models in the research of biological systems and 
new therapeutic targets. Especially tumor angiogenesis and metastasis protocols benefit for 
a much shorter time for the tumor to grow and metastasize than the classical animal models.
The limitations of the model include a restricted number of reagents to work with due to low 
compatibility, nonspecific inflammatory reactions, keratinization of the membrane, and a vas-
cular reaction that interferes with the visualization of vascular modifications. Technical skills 
may be significant to counteract these limitations [16, 17].
The chorioallantoic membrane is the vascularized respiratory extraembryonic tissue of avian 
species. First, this biologic system has been used for embryologic, immunological, and tumor 
grafting studies [18], and more recently, since the discovery of tumor angiogenesis [19], it is 
intensively applied in cancer research [20]. During the stages of embryo development, the 
immunologic, nervous, and nociceptive systems are not fully developed [21]. Several types of 
CAM assay protocols have been developed.
2.2. Uses in biological studies
The method can be applied for bioengineering development, morphology, biochemistry, trans-
plant biology, cancer research, and drug development, but also in immunology, wound healing, 
tissue repair, or drug toxicity [22, 23]. The possibilities of imaging and evaluation have attracted 
many research studies. Nutritional therapeutics is an example of products approved by the U.S. 
Food and Drug Administration (FDA) that were preclinically evaluated in the CAM model [16].
Phytocompounds can be tested in order to evaluate their potential bioavailability, tolerability, 
and lack of irritation effects. For this purpose, the variations of the HET-CAM protocol can be 
applied, according the Interagency Coordinating Committee on the Validation of Alternative 
Methods (ICCVAM) recommendations published in November 2006 in Appendix G of refer-
ence [24]. Our previous evaluations proved its applicability in testing different sets of com-
pounds, i.e., surfactants and aflatoxins [25].
In the attempt of finding new means for cancer chemoprevention, the chorioallantoic membrane 
assay can be used to test natural compounds that could reduce or inhibit several pathways 
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involved in malignancies, especially pro-inflammatory cytokine activation and excessive angio-
genesis. Tumor microenvironment, including inflammation and angiogenesis next to the devel-
opment of new therapeutic targets for these pathological conditions, is intensively researched 
on murine models [26]. Previously, we have evaluated mast cell involvement in the angiogen-
esis process implementing a mastocytoma model on the CAM assay [27], which can be further 
developed for the evaluation of natural compounds on mast cells as key participants in the 
tumor microenvironment.
2.3. General in ovo method
Ex ovo or in ovo techniques are applicable. The ex ovo protocol involves the transfer of the egg 
content on day 3 of incubation into a Petri dish. It facilitates the visualization of the experi-
ment, but the unnatural milieu of development of the embryo is detrimental to the survival 
rate of the specimens. Therefore, we prefer the in ovo protocol and is the type of method 
described here.
Fertilized eggs are horizontally incubated 7 days prior to use, at 37°C, in a controlled wet 
atmosphere. On the third day of incubation, in order to detach the chorioallantoic membrane, 
a volume of 2–3 ml of albumen is aspired through a perforation at the more pointed end of the 
eggs. The hole is resealed and returned to the incubator. The next day, a window is cut and 
resealed on the superior side of the shell. The eggs are returned to incubation until the day of 
the experiment [28]. Generally, 5–10 eggs are used for each test sample. Samples are applied 
inside a sterile plastic ring on the surface of the membrane. Samples are applied in triplicate. 
In ovo investigation by means of a stereomicroscope is performed throughout the experiment. 
Photographs are recorded for further analysis (Figure 2).
Starting with day 11 of incubation, samples can be considered active on excessive angiogen-
esis. The rapid growth of the vessels occurs during days 7–11; therefore, applying substances 
during this interval can be evaluated in terms of antiangiogenic effects. Morphometric evalu-
ation of the angiogenic reaction can be conducted using a 0–5 arbitrary scale, the mean values 
expressing the vascular density around the site of application [20]. Finally, specimens are 
sacrificed and membranes are submitted to histological and immunohistological evaluation. 
On slides with immunohistochemical marked vessels, the mean microvascular density can be 
determined using the hotspot method, and counting the blood vessels, to calculate an antian-
giogenic index, with the aid of the formula: AAI = 1 – No
BVtest
/No
BVcontrol,
 AAI = antiangiogenic 
index, BV = blood vessels [29].
2.4. Tumor angiogenesis model on CAM
Tumor cells are used on the CAM in order to obtain tumors, to study their microenvironment 
and the effects that phytochemicals might have. Tumor grafts can be used as well. Usually, 
cultured cancer cells are inoculated on the surface of the CAM, on day 10 of incubation, after 
being trypsinized and resuspended in culture medium to final concentrations in the range of 
105–106 ml−1. Cells can be applied directly on the CAM using a plastic ring for localizing the 
cells or using Matrigel impregnated with cells. Further, test compound solutions diluted with 
minimal DMSO (dimethyl sulfoxide) concentration in phosphate buffer can be applied on the 
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same spot as the cancer cell samples. In ovo stereomicroscopic follow-up is performed daily to 
register the changes in the vascular response around the tumor developing area that will be 
used for the morphometric analysis. On the final day of the experiment, after sacrificing the 
embryos, tumor masses are measured; the chorioallantoic membrane, the formed tumors, and 
some organs suspected to have metastasis are harvested and histologically processed.
In order to observe morphologic changes in the chorioallantoic membrane, hematoxylin 
eosin staining is analyzed. Different panels of immunohistochemical markers can be further 
applied: tumor cell markers and specific antibodies for different key proteins involved in 
the tumor microenvironment (e.g., endothelial cell marker-factor VIII, smooth muscle actin 
(SMA) marker, vascular endothelial growth factors, and its receptors, mast cells marker—
Tryptase, the proliferation marker—Ki67). Results can reveal molecular modifications and 
serve to vascular density quantification.
Our experience is related to testing phytocompounds and plant extracts for the effect on angio-
genesis. Using the angiogenesis method in the rapid stage of CAM development, we found 
that pentacyclic triterpenes, betulinic (BA) acid, and betulin (Bet) in various formulations with 
cyclodextrin and in nanoemulsion are potential antiangiogenic compounds, acting differ-
ently, both through direct and indirect mechanisms [31, 32]. Immunohistochemical staining 
for smooth muscle actin (SMA) on the specimens treated with betulin in nanoemulsion, next 
Figure 2. Chorioallantoic membrane assay—in ovo practical approach: incubation of the eggs (a–c); albumen removal, 
shell opening, and resealing (d–f); visualization of the CAM, sample application, and sample application inside a plastic 
ring (g–i) [30].
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to blank and control samples, are shown in Figure 3. The low expression of the marker in 
the betulin-treated specimen indicates a minimal implication of pericytes in the angiogenesis 
process [32]. On the contrary, we found that betulinic acid determined rapid maturation of the 
vessels and high levels of SMA [31]. We also evaluated triterpenes and other types of natural 
compounds in melanoma models on CAM, which confirms the inhibitory effect on tumor 
angiogenesis (data not published).
Most studies that use the CAM assay are evaluated through stereomicroscopy that allows a 
series of quantitative measurements, and by histologic an immunohistological interpretation. 
Advances in the evaluation techniques include fluorescence microscopy, confocal micros-
copy, microCT scanning, and imaging, in situ hybridization (ISH), quantitative PCR (qPCR) 
determination of specific targets [16, 33].
3. Phytocompounds targeting cancer angiogenesis: in vitro, on the 
chorioallantoic membrane assay, in animal model
Chemicals derived from plant sources as well as various types of extracts have been already 
investigated for their effects on angiogenesis and on cancer. Currently, based on the failure 
of the approved therapeutics and also by crediting the traditional medicine philosophy that 
pathologies are imbalances that have to be rebalanced, the idea of multiple targeting through 
synergetic phytocompounds mixtures is gaining more attention. Extensive research is being 
dedicated to the understanding of their mechanism and their efficacy using in vitro and in 
vivo methods. The most in depth evidence comes from the results on cell cultures. In vivo 
methods also offer other accurate data on their effects. The chorioallantoic membrane assay 
is being used by more and more researchers for the evaluation of plant-derived chemicals or 
extracts. Correlations can be made using the results obtained for in vitro, animal and CAM 
assays, which will improve the knowledge and the future analysis to perform for the active 
compounds. We reviewed here some of the most investigated phytocompounds concerning 
the results obtained on all the three experimental models (Table 1).
Figure 3. Light microscopic evaluation of CAM sections from ID 11 smooth muscle actin marker: (a) blank specimen, 
×40, (b) control specimen treated with nanoemulsion, ×40, (c) specimen treated with betulin in nanoemulsion, ×40 [32].
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Phytochemical 
class
Compound Chemical structure Plant source In vitro effects Effects on CAM In vivo effects
Polyphenols Curcumin Curcuma longa 
L.
MiaPaCa-2; BxPC-3; Panc-1; 
MPanc-96 prostate cancer 
cell lines
Reduced expression of 
NF-κB
[34]
Angiogenesis 
inhibitor on small 
capillaries [35]
Athymic nude mice xenograft 
with prostate cancer cells
Reduced expression of 
NFκB-p65, STAT3 and SRC;
Reduced expression of 
ANXA2 and VEGFR2
[36]
Epigallocatechin-
gallate
Camellia 
sinensis L.
Hepatocellular carcinoma
Inhibition of the VEGF-
VEGFR axis
[37]
Inhibition of 
fibroblast growth 
factor (FGF) and 
inhibition of mean 
branch formation 
and tumor weight 
of neuroblastoma-
induced 
angiogenesis
[38]
BGC-823 human gastric 
cancer xenograft mice model
Reduction of VEGF
[39]
Phloroglucinol 
derivative
Hyperforin Hypericum 
perforatum L.
BAE—bovine aortic 
endothelial cell
MDA-MB231 human breast 
cancer and NIH-3T3 mouse 
fibroblast cell
Inhibition of capillary tube 
formation; Inhibition of 
urokinase and MMP2
[40]
Multiple target 
angiogenesis 
inhibitor
[40]
Wistar rats inoculated with 
MT-450 at mammary tumor 
cells
Suppression
tumor-induced 
lymphangiogenesis
[41]
Stilbene 
phytoalexin 
derivative
Resveratrol Vitis vinifera L.,
Polygonum 
cuspidatum L.
YUZAZ6, M14, A375
melanoma cell lines
Downregulation of VEGF 
and upregulation of TSP1
[42]
Significant 
reduction in 
angiogenesis in 
higher doses
[43]
C57BL/6 Mice inoculated with 
Lewis lung carcinoma cells
Inhibition of 
neovascularization
[44]
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Phytochemical 
class
Compound Chemical structure Plant source In vitro effects Effects on CAM In vivo effects
Phenols Carnosic acid Rosmarinus 
officinalis L
HT-1080 Human 
fibrosarcoma cells,
HL60 Human promyelocytic
leukemia cells, HUVECs cells
Inhibition of capillary tube 
formation; Decrease in the 
endothelial cells MMP-2 
activity
[45]
Antiangiogenic 
effect; emphasized 
activity for carnosic 
acid
[45]
DMBA-induced hamster 
buccal Pouch carcinogenesis
Suppressed expression 
of Cyclin D1 and NFκB; 
modulation of VEGF
[46]
Carnosol Rosmarinus 
officinalis L
HT-1080 Human 
fibrosarcoma cells,
HL60 Human promyelocytic
leukemia cells, HUVECs cells
capillary tube formation; 
Decrease in the endothelial 
cells MMP-2 activity
[45]
Antiangiogenic 
effect; emphasized 
activity for carnosic 
acid
[45]
n/a
Capsaicin Capsicum sp. Hy-A549CoCl2-stimulated 
A549 lung cancer cells
Inhibition of VEGF by 
downmodulation of HIF-1α; 
Increased p53 level
[47]
Potent inhibitor 
of tumor-induced 
angiogenesis
[48]
C57BL/6 mice
Inhibition of VEGF and 
hemoglobin
[48]
Isoflavones Daidzein Trifolium 
pratense L., 
Glycine maxima 
L.
LNCaP, PC-3, and DU-145 
PCa cells -
Down-regulation of ECGF1, 
FGF1, IGF1, FGFR3, IL-1β, 
IL-6, IL-8, PECAM1[49]
Antiangiogenic 
effect, anti-
inflammatory effect 
with no membrane-
irritating and toxic 
side effects[50]
n/a
Genistein Trifolium 
pratense L., 
Glycine maxima 
L.
BME cloned bovine
microvascular
endothelial cells
Inhibition of bFGF
[51]
Antiangiogenic 
effect, anti-
inflammatory effect 
with no membrane-
irritating and toxic 
side effects[50]
BALB/C nu/nu mice 
inoculated with Bel 7402 
hepatocellular carcinoma
Significant decrease of 
positive unit (PU) of the 
microvessels[52]
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Phytochemical 
class
Compound Chemical structure Plant source In vitro effects Effects on CAM In vivo effects
Flavonoids Quercetin Camelia 
sinensis L., 
Angelica keiskei 
Momordica 
cochinchinensis,
PC-3 prostate cells
Inhibition of VEGF
[53]
Potent angiogenesis 
inhibitor [53]
DMBA-induced experimental 
mammary carcinoma in rats
Inhibition of H-ras protein; 
inhibition of VEGF and bFGF
[54]
Naringenin Citrus sp. Aspc-1 and panc-1 prostate 
cancer cells
Inhibition of TGF-β1-induced 
migration; Decreased 
expression of MMP2 and 
MMP9 proteins
[55]
Potent angiogenesis 
inhibitor
[56]
n/a
Apigenin Entada africana,
Matricaria 
chamomilla L
PC-3 and DU145 prostate 
cancer cells
Inhibition of HIF-1α and 
VEGF
LNCaP prostate cancer cells, 
HCT-8 colon cancer cells, and 
MCF-7breast cancer cells
Inhibition of hypoxia-induced 
HIF-1α and VEGF[57]
Promising 
antiangiogenic 
effect
[58]
BALB/cA-nu nude mice 
injected with PC-3 prostate 
cancer cells and OVCAR-3 
ovarian cancer cells
Inhibition of blood vessels 
formation; Inhibition of 
hemoglobin levels [57]
Isoliquiritigenin Glycyrrhiza 
glabra L
ACC-M, ACC-2 adenoid 
cystic carcinoma cells 
and EAhy926 endothelial 
hybridoma cell line
Prevention of tube formation; 
Downregulation of VEGF
[59]
Angiogenesis 
suppressor [60]
BALB/c nude mice injected 
with ACC-M cells
Reduction in S6 
phosphorylation; Decreased 
VEGF; Inhibition of the mTOR 
signaling pathway[59]
Silibinin Silybum 
marianum L
SW480, HT-29 and LoVo 
colorectal cancer cells
Inhibition of NF-κB; 
Reduction of MMP9, COX-2 
and VEGF[61]
dose-dependent 
suppressive on 
angiogenesis [62]
A/J mice with Urethane-
induced lung tumors
Inhibition of new microvessels 
formation; Decreased levels of 
IL-1α,-6, -9, -13, -16, IFN-γ and 
TNF-α[63]
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Phytochemical 
class
Compound Chemical structure Plant source In vitro effects Effects on CAM In vivo effects
Alkaloids Vinblastine Vinca sp. Human neuroblastoma
cell lines
Downmodulation of VEGF 
and VEGF-R2
[64]
Angiostatic activity 
[64]
Athymic (Nude-nu) mice 
injected with GI-LI-N cells
Decrease of CD31-
positive blood vessels; 
Downmodulation of VEGF 
and VEGF-R2[64]
Vincristine Vinca sp. Glioblastoma cells—
decreased expression of 
VEGF mRNA and the level 
of HIF-1α protein
[65]
Antiangiogenic 
effects in 
neuroblastoma 
tumors in high 
doses
[66]
Swiss nu/nu mice injected 
with Caki-l and Caki-2 renal 
carcinoma cells
Inhibition of angiogenesis
[67]
Pentacyclic 
triterpenes
Betulin Betula pendula, 
Prunus dulcis
Apoptotic induction in MCF-
7, A431 [68]
Strong direct 
antiangiogenic 
effects
[32]
Balb/C mice DMBA/TPA skin 
carcinoma model
Decreased expression of 
VEGF
[32]
Betulinic acid Betula pendula, 
Prunus dulcis
SK-MEL2 melanoma and 
LNCaP prostate cancer cells -
Decreased expression of Sp1, 
Sp3, Sp4, and VEGF
[69]
Strong 
antiangiogenic 
effects
[31]
Athymic nude mice
with LNCaP cells as 
xenografts
Tumor tissue less vascular; 
Decreased expression of Sp1,
Sp3, Sp4, AR, and VEGF [69]
Tetracyclic 
Triterpenoid 
saponins
Ginsenoside Rg3 Panax ginseng Eca-109—human esophageal 
carcinoma cell line and 786-0 
renal cell carcinoma cell line
Downregulation of VEGF 
expression via COX-2 
pathway; Reduction of 
STAT3 phosphorylation; 
Decreased HIF-1α protein 
expression in Eca-109 
cells[70]
Strong, multi-
target inhibition of 
neovascularization, 
without affecting 
endothelial cell 
proliferation; lack 
of cytotoxicity
[71]
C57BL/6 mice injected with 
LLC Lewis lung carcinoma 
cells
Decreased tube formation 
of circulating progenitor 
cells; Suppression of VEGF 
dependent p38 and ERK 
signal pathways [72]
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Phytochemical 
class
Compound Chemical structure Plant source In vitro effects Effects on CAM In vivo effects
Flavones Baicalein Scutellaria 
baicalensis 
Georgi
H-460 cells assessed using 
BrdU assay Significant 
antiproliferative and pro 
apoptotic; inhibit bFGF-
induced HUVEC
tube formation in Matrigel 
stronger than baicalin [74, 
75]
Dose-dependent 
antiangiogenic 
activity
[74]
H-460 athymic nude mice, 
tumor growth and survival 
low expression of 12-LOX, 
VEGF and FGFR-2 gene [73]
Baicalin Scutellaria 
baicalensis 
Georgi
Growth and survival, 
MMP-2 expression, inhibit 
bFGF-induced HUVEC
tube formation in Matrigel 
[74]; increases VEGF 
expression by activating the 
ERRα/PGC-1α pathway [75]
Dose-dependent 
antiangiogenic 
activity
[74]
Inhibit growth of S180 solid 
tumor in mice [76]
Steroids Withaferin A Withania 
somnifera 
Dunal 
Antiangiogenic activity in 
primary endothelial cells 
HUVEC [77]
Significant 
antiangiogenic 
activity
[78]
Inhibits FGF-2 Induced 
angiogenesis in C57BL/6J 
mice [77]
Table 1. Common phytocompounds with in vitro and in vivo antiangiogenic activity.
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4. Clinical trials correlation
Implementation of clinical trials is vital for the validation and future use of the active phyto-
compounds as additional therapies to the oncologic protocols or as chemopreventive strate-
gies. These types of experiments are difficult to implement and therefore not many trials are 
finalized for the evaluation of antiangiogenic effect in cancer. Two of the above-listed phyto-
chemicals (Table 1) benefit from large investigations among which some are clinical trials, 
but the modulation of the angiogenic process does not appear as a distinct evaluation, cancer 
effects being the first ones to be described.
Most of the controlled clinical trials of curcumin supplementation in cancer patients aimed to 
determine its feasibility, tolerability, safety, and to provide early evidence of efficacy [79]. For 
patients with advanced colorectal cancer, oral doses up to 3.6 g/day for 4 months were well 
tolerated, although the systemic bioavailability of oral curcumin was low [80]. For this dose, 
trace levels of curcumin metabolites were measured in liver tissue, but curcumin itself was 
not detected [81]. These findings suggested that oral curcumin is effective as a therapeutic 
agent in cancers of the gastrointestinal tract. Other trials found that combining curcumin with 
anticancer drugs like gemcitabine in pancreatic cancer [82], docetaxel in breast cancer [83], 
and imatinib in chronic myeloid leukemia may confer additional benefits to conventional 
drugs against different types of cancer.
Green tea made from Camellia sinensis L. leaves, originated in China, is one of the most 
extensively consumed beverages and achieved significant attention due to health benefits 
against cancer. Representative compounds are polyphenols and catechins with thera-
peutic potential against cancer [84]. Recent clinical trials proved that green tea extract 
and epigallocatechin gallate (EGCG) can be active in several forms of cancer. There is an 
increasing trend to employ green tea extract and EGCG as conservative management for 
patients diagnosed with less advanced prostate cancer. Combinations of chemopreventive 
agents should be carefully investigated because mechanisms of action may be additive or 
synergistic [85]. Several clinical examinations reported different molecular mechanisms 
regarding green tea beneficial effects against oral cancer chemoprevention [86–88]. Lung 
cancer induction may also be inhibited by tea polyphenols. Some studies suggest that 
individuals who never drank green tea have an elevated lung cancer risk compared to 
those who drank green tea at least one cup per day, and the effect is more pronounced in 
smokers [88]. Hepatocellular carcinoma (HCC) usually develops in a cirrhotic liver due 
to hepatitis virus infection. Green tea catechins (GTCs) may possess potent anticancer 
and chemopreventive properties for a number of different malignancies, including liver 
cancer. Antioxidant and anti-inflammatory activities are key mechanisms through which 
GTCs prevent the development of neoplasms, and they also exert cancer chemopreven-
tive effects by modulating several signaling transduction and metabolic pathways where 
angiogenesis is exacerbated. Several interventional trials in humans have shown that 
GTCs may ameliorate metabolic abnormalities and prevent the development of precancer-
ous lesions [89].
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5. Conclusion
Currently, a great number of natural compounds are being investigated for their potential 
effectiveness in controlling tumor angiogenesis and therefore the reduction of tumor growth 
and metastasis. Observing the high number of molecular pathways that are deregulated in 
tumor angiogenesis and that many phytocompounds are active on several key factors, it is rec-
ommendable that more in vivo studies should investigate mixture of compounds for broader 
targeting, having eventually lower secondary effects and resistance. The optimal experimen-
tal technique is an important factor in order to get a useful output. More types of assays are 
always a good choice, including in vivo assays. The chorioallantoic membrane protocol is a 
good candidate for one type of “golden standardized method” in tumor angiogenesis, being a 
versatile, rapid, easy, and cheap method to apply in the research of phytocompounds. A great 
number of plant-derived chemicals, alone or in combination, are studied using this method, 
but standardization, next to applying new analysis techniques will outcome useful data that 
will be easier translated to clinical trials.
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